These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18001616)

  • 1. SPARCL: the glimmer of statins for stroke risk reduction.
    Armani A; Toth PP
    Curr Atheroscler Rep; 2007 Nov; 9(5):347-51. PubMed ID: 18001616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the SPARCL trial and its subanalyses.
    Welch KM
    Curr Atheroscler Rep; 2009 Jul; 11(4):315-21. PubMed ID: 19500496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
    Amarenco P; Bogousslavsky J; Callahan AS; Goldstein L; Hennerici M; Sillsen H; Welch MA; Zivin J;
    Cerebrovasc Dis; 2003; 16(4):389-95. PubMed ID: 14584489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
    Huisa BN; Stemer AB; Zivin JA
    Vasc Health Risk Manag; 2010 Apr; 6():229-36. PubMed ID: 20407630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
    Arca M
    Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Chaturvedi S; Zivin J; Breazna A; Amarenco P; Callahan A; Goldstein LB; Hennerici M; Sillesen H; Rudolph A; Welch MA;
    Neurology; 2009 Feb; 72(8):688-94. PubMed ID: 18768917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin in prevention of stroke and transient ischaemic attack.
    Amarenco P
    Expert Opin Pharmacother; 2007 Nov; 8(16):2789-97. PubMed ID: 17956199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atorvastatin in secondary prevention].
    Ongen Z; Yilmaz Y; Karadağ B
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():23-8. PubMed ID: 19404047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Important aim of statin therapy: ischemic cardiovascular event (stroke)].
    Császár A
    Ideggyogy Sz; 2008 Jul; 61(7-8):239-43. PubMed ID: 18763479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
    Arca M; Gaspardone A
    Drugs; 2007; 67 Suppl 1():29-42. PubMed ID: 17910519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statins in the secondary prevention of stroke: New evidence from the SPARCL Study].
    Castilla-Guerra L; Fernández-Moreno Mdel C; López-Chozas JM
    Clin Investig Arterioscler; 2016; 28(4):202-8. PubMed ID: 26150172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.